Title: Diagnosis and treatment of autoimmune hepatitis
Abstract: HepatologyVolume 36, Issue 2 p. 479-497 Aasld Practice GuidelinesFree Access Diagnosis and treatment of autoimmune hepatitis Albert J. Czaja 200 First Street S.W., Corresponding Author Albert J. Czaja 200 First Street S.W. [email protected] Divisions of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MNRochester, MN 55905. fax: 507-284-0538.===Search for more papers by this authorDeborah K. Freese, Deborah K. Freese Divisions of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN Pediatric Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MNSearch for more papers by this author Albert J. Czaja 200 First Street S.W., Corresponding Author Albert J. Czaja 200 First Street S.W. [email protected] Divisions of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MNRochester, MN 55905. fax: 507-284-0538.===Search for more papers by this authorDeborah K. Freese, Deborah K. Freese Divisions of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN Pediatric Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MNSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2002.34944Citations: 425AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995; 40: 435– 456.MEDLINE 2 Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824– 1832.MEDLINE 3 Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000; 174: 250– 259.MEDLINE 4 Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001; 96: 1224– 1231.MEDLINE 5 Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99– 103.MEDLINE 6 Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999; 68: 253– 256.MEDLINE 7 Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, Everhart J, et al. Acute allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638– 645.MEDLINE 8 Czaja AJ, Dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci 1998; 43: 2149– 2155.MEDLINE 9 Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, Mowat AP, et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 1997; 25: 541– 547.MEDLINE 10 Fainboim L, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C, Badia I, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRB1*1301) haplotype. Hum Immunol 1994; 41: 146– 150.MEDLINE 11 Seki T, Ota M, Furuta S, Fukushima H, Kondo T, Hino K, Mizuki N, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992; 103: 1041– 1047.MEDLINE 12 Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Laudanna AA, Kalil J. Different HLA profiles confer susceptibility to autoimmune hepatitis type 1 and 2. Am J Gastroenterol 1998; 93: 1394– 1395.MEDLINE 13 Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK. Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J Gastroenterol Hepatol 2001; 16: 1144– 1148.MEDLINE 14 Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 2001; 96: 3390– 3394.MEDLINE 15 Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR, Schoenfield LJ. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820– 833.MEDLINE 16 Mistilis SP, Skyring AP, Blackburn CRB. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med 1968; 17: 214– 223.MEDLINE 17 Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735– 737.MEDLINE 18 Schalm SW, Korman MG, Summerskill WHJ, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977; 22: 973– 980.MEDLINE 19 DeGroote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978; 19: 510– 513.MEDLINE 20 Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983; 85: 713– 717.MEDLINE 21 Crapper RM, Bhathal PS, Mackay IR, Frazer IH. "Acute" autoimmune hepatitis. Digestion 1986; 34: 216– 225.MEDLINE 22 Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 1989; 11: 303– 307.MEDLINE 23 Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994; 21: 866– 871.MEDLINE 24 Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Ped Gastroenterol Nutrition 1990; 11: 138– 140. 25 Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159– 185.MEDLINE 26 Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992; 15: 215– 221.MEDLINE 27 González-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, Rosen CB, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transplantation 2001: 4: 302– 310. 28 Ratziu V, Samuel D, Sebagh M, Farges O, Saliba F, Ichai P, Farahmand H, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999; 30: 131– 141.MEDLINE 29 Ahmed M, Mutimer D, Hathaway M, Hubscher S, McMaster P, Elias E. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transplantation Proceedings 1997; 29: 496.MEDLINE 30 Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984; 37: 363– 365.MEDLINE 31 Wright HL, Bou-Abboud CF, Hassanein T, Block GD, Demetris AJ, Starzl TE, Van Thiel DH. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992; 53: 136– 139.MEDLINE 32 Devlin J, Donaldson P, Portmann B, Heaton N, Tan K-C, Williams R. Recurrence of autoimmune hepatitis following liver transplantation. Liver Transplantation Surg 1995; 1: 162– 165. 33 Prados E, Cuervas-Mons V, de la Mata M, Fraga E, Rimola A, Prieto M, Clemente G, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998; 66: 1645– 1650.MEDLINE 34 Gotz G, Neuhaus R, Bechstein WO, Lobeck H, Berg T, Hopf U, Neuhaus P. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation Proceedings 1999; 31: 430– 431.MEDLINE 35 Birnbaum AH, Benkov KJ, Pittman NS, McFarlane-Ferreira Y, Rosh JR, LeLeiko NS. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 1997; 25: 20– 25.MEDLINE 36 Johnson PJ, McFarlane IG, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, Chapman RW, et al. Meeting Report. International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998– 1005.MEDLINE 37 Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929– 938.MEDLINE 38 Frazer IH, Mackay IR, Bell J, Becker G. The cellular infiltrate in the liver in autoimmune chronic active hepatitis: analysis with monoclonal antibodies. Liver 1985; 5: 162– 172.MEDLINE 39 Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572– 577.MEDLINE 40 Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567– 571.MEDLINE 41 Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997; 26: 459– 466.MEDLINE 42 Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687– 692.MEDLINE 43 Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360– 365.MEDLINE 44 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31: 1231– 1238.MEDLINE 45 Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001; 34: 659– 665.MEDLINE 46 Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001; 49: 589– 594.MEDLINE 47 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198– 206.MEDLINE 48 Czaja AJ. Autoantibodies. Bailliere's Clin Gastroenterol 1995; 9: 723– 744. 49 Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001; 120: 239– 249.MEDLINE 50 Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996; 41: 305– 314.MEDLINE 51 Bianchi FB, Cassani F, Lenzi M, Ballardini G, Muratori L, Giostra F, Zauli D. Impact of International Autoimmune Hepatitis Group scoring system in definition of autoimmune hepatitis. An Italian experience. Dig Dis Sci 1996; 41: 166– 171.MEDLINE 52 Toda G, Zeniya M, Watanabe F, Imawari M, Kiyosawa K, Nishioka M, Tsuji T, Omata M. Present status of autoimmune hepatitis in Japan- correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol 1997; 26: 1207– 1212.MEDLINE 53 Miyakawa H, Kitazawa E, Abe K, Kawaguchi N, Fuzikawa H, Kikuchi K, Kato M, et al. Chronic hepatitis C associated with anti-liver/kidney microsome-1 antibody is not a subgroup of autoimmune hepatitis. J Gastroenterol 1997; 32: 769– 776.MEDLINE 54 Dickson RC, Gaffey MJ, Ishitani MB, Roarty TP, Driscoll CJ, Caldwell SH. The international autoimmune hepatitis score in chronic hepatitis C. J Viral Hep 1997; 4: 121– 128. 55 Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A, Schrumpf E. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996; 23: 1369– 1376.MEDLINE 56 Omagari K, Masuda J, Kato Y, Nakata K, Kanematsu T, Kusumoto Y, Mori I, et al. Re-analysis of clinical features of 89 patients with autoimmune hepatitis using the revised scoring system proposed by the International Autoimmune Hepatitis Group. Intern Med 2000; 39: 1008– 1012.MEDLINE 57 Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999; 30: 394– 401.MEDLINE 58 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993; 104: 1755– 1761.MEDLINE 59 Czaja AJ. Chronic active hepatitis: the challenge for a new nomenclature. Ann Intern Med 1993; 119: 510– 517.MEDLINE 60 Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993; 105: 1522– 1528.MEDLINE 61 Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733– 1740.MEDLINE 62 Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, Mowat AP, et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 1997; 25: 541– 547.MEDLINE 63 Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544– 553.MEDLINE 64 Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107: 200– 207.MEDLINE 65 Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 1998; 122: 993– 999.MEDLINE 66 Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997; 42: 1688– 1696.MEDLINE 67 Bernstein RM, Neuberger JM, Bunn CC, Callender ME, Hughes GRV, Williams R. Diversity of autoantibodies in primary biliary cirrhosis and chronic active hepatitis. Clin Exp Immunol 1984; 55: 553– 560.MEDLINE 68 Chou M-J, Lee S-L, Chen T-Y, Tsay GJ. Specificity of antinuclear antibodies in primary biliary cirrhosis. Ann Rheum Dis 1995; 54: 148– 151.MEDLINE 69 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 1996; 24: 52– 59.MEDLINE 70 Czaja AJ, Santrach PJ, Moore SB. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001; 46: 140– 147.MEDLINE 71 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18: 816– 822.MEDLINE 72 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995; 108: 157– 164.MEDLINE 73 Maddrey WC, Boitnott JK. Drug-induced chronic liver disease. Gastroenterology 1977; 72: 1348– 1353.MEDLINE 74 Seeff LB. Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis 1981; 1: 104– 115.MEDLINE 75 Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989; 9: 193– 197.MEDLINE 76 Kurki P, Gripenberg M, Teppo A-M, Salaspuro M. Profiles of antinuclear antibodies in chronic active hepatitis, primary biliary cirrhosis and alcoholic liver disease. Liver 1984; 4: 134– 138.MEDLINE 77 Konikoff F, Isenberg DA, Barrison I, Theodor E, Shoenfeld Y. Antinuclear autoantibodies in chronic liver diseases. Hepato-gastroenterol 1989; 36: 341– 345. 78 Whittingham S, Irwin J, Mackay IR, Smalley M. Smooth muscle autoantibody in "autoimmune" hepatitis. Gastroenterology 1966; 51: 499– 505.MEDLINE 79 Bottazzo GF, Florin-Christensen A, Fairfax A, Swana G, Doniach D, Groeschel-Stewart U. Classification of smooth muscle autoantibodies (SMA) detected by immunofluorescence. J Clin Path 1976; 29: 403– 410.MEDLINE 80 Toh B-H. Smooth muscle autoantibody and autoantigens. Clin Exp Immunol 1979; 38: 621– 628.MEDLINE 81 Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068– 1073.MEDLINE 82 Homberg J-C, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7: 1333– 1339.MEDLINE 83 Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290– 1295.MEDLINE 84 Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370– 1378.MEDLINE 85 Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zum Buschenfelde K-H, Meyer UA, Eichelbaum M. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology 1990; 12: 127– 132.MEDLINE 86 Lohr H, Manns M, Kyriatsoulis A, Lohse AW, Trautwein C, Meyer zum Buschenfelde K-H, Fleischer B. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991; 84: 297– 302.MEDLINE 87 Todros L, Touscoz G, D'Urso N, Durazzo M, Albano E, Poli G, Baldi M, et al. Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). Clinical characterization from idiopathic LKM-positive disorders. J Hepatol 1991; 13: 128– 131.MEDLINE 88 Lunel F, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Coz Y, Valla D, et al. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992; 16: 630– 636.MEDLINE 89 Giostra F, Manzin A, Lenzi M, Francesconi R, Solforosi L, Manotti P, Muratori L, et al. Low hepatitis C viremia in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. J Hepatol 1996; 25: 433– 438.MEDLINE 90 Mackie FD, Peakman M, Yun M, Sallies R, Smoth H, Davies ET, Mieli-Vergani G, et al. Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus. Gastroenterology 1994; 106: 1672– 1675.MEDLINE 91 Reddy RK, Krawitt EL, Homberg JC, Jeffers LJ, de Medina M, Chastenay B, Poupon R, et al. Absence of anti-LKM1 in hepatitis C viral infection in the United States. J Viral Hepat 1995; 2: 175– 179.MEDLINE 92 Michitaka K, Durazzo M, Tillmann HL, Walker D, Philipp T, Manns MP. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994; 106: 1603– 1610.MEDLINE 93 Gerotto M, Pontisso P, Giostra F, Francesconi R, Muratori L, Ballardini G, Lenzi M, et al. Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. J Hepatol 1994; 21: 273– 276.MEDLINE 94 Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of the anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993; 104: 1762– 1767.MEDLINE 95 Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997; 92: 2197– 2200.MEDLINE 96 Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Carrilho FJ, Farias AQ, Palacios SA, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999; 94: 1906– 1913.MEDLINE 97 Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995; 90: 1206– 1211.MEDLINE 98 Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type 1 autoimmune hepatitis. Gastroenterology 1995; 108: 1159– 1166.MEDLINE 99 Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CGM. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411– 417.MEDLINE 100 Zauli D, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G, Muratori L, Bianchi FB. Anti-neutrophil cytoplasmic antibodies in type 1 and type 2 autoimmune hepatitis. Hepatology 1997; 25: 1105– 1107.MEDLINE 101 LaBrecque DR, Phillips MJP, Ippolito LA, Mitros FA, Goeken JA. Antineutrophil cytoplasmic antibody and chronic liver disease [abstract]. Hepatology 1999; 30(Part 2): 428A. 102 Duerr RH, Targan SR, Landers CJ, LaRusso NF, Lindsay KL, Wiesner RH, Shanahan F. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 1385– 1391.MEDLINE 103 Bansi D, Chapman R, Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol 1996; 24: 581– 586.MEDLINE 104 Lidman K, Biberfield G, Fagraeus A, Norberg R, Tortensson R, Utter G, Carlsson L, et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 1976; 24: 266– 272.MEDLINE 105 Cancado ELR, Vilas-Boas LS, Abrantes-Lemos CP, Novo NF, Porta G, Da Silva LC, Laudanna AA. Heat serum inactivation as a mandatory procedure for antiactin antibody detection in cell culture. Hepatology 1996; 23: 1098– 1104.MEDLINE 106 McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol 1984; 55: 347– 354.MEDLINE 107 Treichel U, Poralla T, Hess G, Manns M, Meyer zum Buschefelde K-H. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology 1990; 11: 606– 612.MEDLINE 108 Poralla T, Treichel U, Lohr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 1991; 11: 215– 222.MEDLINE 109 McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984; 2: 954– 956.MEDLINE 110 Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Buschenfelde K-H, Poralla T. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol 1993; 19: 55– 63.MEDLINE 111 Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733– 1740.MEDLINE 112 Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, Porta G, et al. Establishment of a standardized SLA/LP immunoassay: specificity for autoimmune hepatitis, worldwide occurrence and clinical characteristics. Gut (in press). 113 Wies I, Brunner S, Henninger J, Herkel J, Meyer zum Buschenfelde KH, Lohse AW. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510– 1515.MEDLINE 114 Costa M, Rodriques-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNA(Ser)Sec complex recognized by autoantibodies from patients with type 1 autoimmune hepatitis. Clin Exp Immunol 2000; 121: 364– 374.MEDLINE 115 Kernebeck T, Lohse AW, Grotzinger J. A bioinformatical approach suggests the function of the autoimmune hepatitis target soluble liver antigen/liver pancreas. Hepatology 2001; 34: 230– 233.MEDLINE 116 Kanzler S, Weidemann C, Gerken G, Lohr HF, Galle PR, Meyer zum Buschenfelde KH, Lohse AW. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999; 31: 635– 640.MEDLINE 117 Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413– 419.MEDLINE 118 Volkmann M, Martin L, Baurle A, Heid H, Strassburg CP, Trautwein C, Fiehn W, et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically reacts with sera from patients with autoimmune hepatitis. Hepatology 2001; 33: 591– 596.MEDLINE 119 Lapierre P, Hajoui O, Homberg J-C, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116: 643– 649.MEDLINE 120 Muratori L, Sztul E, Muratori P, Gao YS, Ripalti A, Ponti C, Lenzi M, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001; 34: 494– 501.MEDLINE 121 Pelli N, Fensom AH, Slade C, Boa F, Mieli-Vergani G, Vergani D. Argininosuccinate lyase: a new autoantigen in liver disease. Clin Exp Immunol 1998; 114: 455– 461.MEDLINE 122 Abuaf N, Johanet C, Chretien P, Martini E, Soulier E, Laperche S, Homberg JC. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992; 16: 892– 898.MEDLINE 123 Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg J-C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988; 8: 1662– 1666.MEDLINE 124 Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995; 21: 58– 62.MEDLINE 125 Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42: 721– 726.MEDLINE 126 Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292– 294.MEDLINE 127 Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993; 18: 1– 9.MEDLINE 128 Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701– 706.MEDLINE 129 Strettell MDJ, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, Williams R. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112: 2028– 2035.MEDLINE 130 Czaja AJ, Strettell MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317– 323.MEDLINE 131 Czaja AJ, Rakela J, Hay JE, Moore SB. Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1990; 98: 1587– 1593.MEDLINE 132 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502– 1507.MEDLINE 133 Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH, De Virgiliis S, et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1997; 82: 1353– 1361.MEDLINE 134 Clemente MG, Meloni A, Obermayer-Staub P, Frau F, Manns MP, De Virgiliis S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998; 114: 324– 328.MEDLINE 135 Obermayer-Straub P, Perheentupa J, Braun S, Kayser A, Barut A, Loges S, Harms A, et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology 2001; 121: 668– 677.MEDLINE 136 Consortium TF-GA. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc finger domains. Nat Genet 1997; 17: 399– 403.MEDLINE 137 Aaltonen J, Borses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type 1 assigned to chromosome 21. Nat Genet 1994; 8: 83– 87.MEDLINE 138 Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJE, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17: 393– 398.MEDLINE 139 Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848– 857.MEDLINE 140 Koretz RL, Lewin KJ, Higgins J, Fagen ND, Gitnick GL. Chronic active hepatitis. Who meets treatment criteria? Dig Dis Sci 1980; 25: 695– 699.MEDLINE 141 Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 1972; 3: 183– 198.MEDLINE 142 Czaja AJ, Taswell HF, Rakela J, Schimek C. Frequency of antibody to hepatitis C virus in asymptomatic HB